Interstitial Cystitis, also known as Painful Bladder Syndrome, is a chronic, painful condition that mostly affects women. While there is no known cure, Elmiron is the only FDA-approved drug to manage the symptoms. Elmiron was originally approved for use by the FDA to treat the symptoms of Painful Bladder Syndrome in 1996.
It was not until 2018 however, that the first research study was published, showing that long-term use of Elmiron was associated with a new type of retinal damage. Further research found similar results and established a reliable link between the long-term use of Elmiron and injury to the center of the retina, in an area of the eye known as the macula.
This newly discovered condition, Retinal Maculopathy, includes symptoms that occur gradually, and may not be immediately obvious. They include dark spots in the field of vision, difficulty adjusting vision to low-light situations, difficulty reading, blurred vision, and even blindness.
The manufacturer of Elmiron, Janssen Pharmaceuticals, ignored reports of vision problems from users of their drug for more than 20 years, and failed to warn doctors or patients of the risks of permanent vision harm.
If you’ve taken Elmiron for more than two years and suffer from any of the symptoms of Retinal Maculopathy, make an appointment to see an ophthalmologist. If you have any questions, contact the experienced product liability lawyers at The Yost Legal Group. We can help you get answers.